Showing results (621-630 of 782) with videos related to

Sort By:
Pageof 79
British Journal of Haematology|April 10, 2008
p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implicationsKenji Ishitsuka, Teru Hideshima, Paola Neri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2009
Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomibMelissa G Ooi, Patrick J Hayden, Vassiliki Kotoula, et al.
Blood|March 5, 2008
Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemiaAldo M Roccaro, Xavier Leleu, Antonio Sacco, et al.
Blood|December 23, 2006
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomibGeorge Mulligan, Constantine Mitsiades, Barb Bryant, et al.
Blood|August 24, 2007
MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclastsSonia Vallet, Noopur Raje, Kenji Ishitsuka, et al.
Blood|October 18, 2002
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myelomaPaul G Richardson, Robert L Schlossman, Edie Weller, et al.
Blood|August 4, 2025
Deciphering neutrophil dynamics in the focal lesion tumor microenvironment to overcome immunosuppression in multiple myelomaJoshua Rivera, Qi Yan, Saeed Daneshmandi, et al.
British Journal of Haematology|January 21, 2017
Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1Michal Bar-Natan, Dina Stroopinsky, Katarina Luptakova, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2024
Improving Collection and Analysis of Overall Survival DataLisa R Rodriguez, Nicole J Gormley, Ruixiao Lu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2008
Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironmentAlissa Huston, Xavier Leleu, Xiaoying Jia, et al.
Pageof 79